- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...

Eli Lilly on Sunday launched a DTC campaign for its injectable diabetes drug Trulicity as it seeks to build market share in the competitive GLP-1 receptor agonist class, which has four other approved ...

INDIANAPOLIS, Dec. 1, 2015 /CNW/ -- New data from a completed Phase 3 trial show Trulicity ® (dulaglutide) solution for injection 1.5 mg plus a sulfonylurea was significantly more effective than a ...

hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Ozempic is generally more effective in lowering blood sugar and ...

Medicare Part D and some Medicare Advantage (Part C) plans may cover Trulicity for managing type 2 diabetes, but coverage specifics depend on the plan’s formulary (drug list). Medicare typically does ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...

TORONTO, Feb. 16, 2016 /CNW/ - Eli Lilly Canada announced the approval of Trulicity™ (dulaglutide), a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of adults ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...